Our findings indicate these medications may improve long-term health for people with PAD, in addition to managing blood sugar and weight loss. In this study, researchers reviewed the health records for more than 2,000 adults with PAD and type 2 diabetes to explore the potential benefits of GLP-1 RA medications
A study published in the New England Journal of Medicine shows that, after 72 weeks, participants without diabetes lost on average: 20.2% of their body weight with tirzepatide (Mounjaro) 13.7% of their body weight with semaglutide (Ozempic) This is a direct side-by-side comparison at the same maximum tolerated dose
Science for Living: What to know about Ozempic and other weight loss drugs UCLA Health
It produces approximately twice the weight loss, requires only weekly rather than daily injections, and has stronger cardiovascular protection data
For short trips, take your dose before or after travel as long as you maintain the 48-hour gap